Baseline and early digital [ 18 F]FDG PET/CT and multiparametric MRI contain promising features to predict response to neoadjuvant therapy in locally advanced rectal cancer patients: a pilot study.
| Title: | Baseline and early digital [ 18 F]FDG PET/CT and multiparametric MRI contain promising features to predict response to neoadjuvant therapy in locally advanced rectal cancer patients: a pilot study. |
|---|---|
| Authors: | Vuijk FA; Department of Surgery, Leiden University Medical Center.; Feshtali Shahbazi S; Department of Radiology, Leiden University Medical Center, Leiden.; Noortman WA; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center.; Biomedical Photonic Imaging Group, University of Twente, Enschede.; van Velden FHP; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center.; Dibbets-Schneider P; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center.; Marinelli AWKS; Department of Surgery, Haaglanden Medisch Centrum, Den Haag.; Neijenhuis PA; Department of Surgery, Alrijne Ziekenhuis, Leiderdorp.; Schmitz R; Department of Surgery, Groene Hart Ziekenhuis, Gouda.; Ghariq E; Department of Radiology, Leiden University Medical Center, Leiden.; Velema LA; Department of Radiation Oncology, Leiden University Medical Center.; Peters FP; Department of Radiation Oncology, Leiden University Medical Center.; Department of Radiation Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam.; Smit F; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center.; Peeters KCMJ; Department of Surgery, Leiden University Medical Center.; Temmink SJD; Department of Surgery, Leiden University Medical Center.; Crobach SALP; Department of Pathology, Leiden University Medical Center.; Putter H; Department of Medical Statistics, Leiden University Medical Center, Leiden.; Vahrmeijer AL; Department of Surgery, Leiden University Medical Center.; Hilling DE; Department of Surgery, Leiden University Medical Center.; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam.; Department of Surgery, Ijsselland Ziekenhuis, Capelle a/d IJssel.; de Geus-Oei LF; Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center.; Biomedical Photonic Imaging Group, University of Twente, Enschede.; Department of Radiation Science & Technology, Technical University Delft, The Netherlands. |
| Source: | Nuclear medicine communications [Nucl Med Commun] 2023 Jul 01; Vol. 44 (7), pp. 613-621. Date of Electronic Publication: 2023 May 03. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8201017 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5628 (Electronic) Linking ISSN: 01433636 NLM ISO Abbreviation: Nucl Med Commun Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Lippincott Williams & Wilkins; Original Publication: London : Chapman and Hall in association with the British Nuclear Medicine Society, c1980- |
| MeSH Terms: | Rectal Neoplasms*/diagnostic imaging ; Rectal Neoplasms*/therapy ; Rectal Neoplasms*/pathology ; Multiparametric Magnetic Resonance Imaging*; Humans ; Fluorodeoxyglucose F18 ; Positron Emission Tomography Computed Tomography ; Neoadjuvant Therapy ; Pilot Projects ; Tomography, X-Ray Computed ; Chemoradiotherapy ; Treatment Outcome ; Radiopharmaceuticals |
| Abstract: | Objective: In this pilot study, we investigated the feasibility of response prediction using digital [ 18 F]FDG PET/computed tomography (CT) and multiparametric MRI before, during, and after neoadjuvant chemoradiation therapy in locally advanced rectal cancer (LARC) patients and aimed to select the most promising imaging modalities and timepoints for further investigation in a larger trial.; Methods: Rectal cancer patients scheduled to undergo neoadjuvant chemoradiation therapy were prospectively included in this trial, and underwent multiparametric MRI and [ 18 F]FDG PET/CT before, 2 weeks into, and 6-8 weeks after chemoradiation therapy. Two groups were created based on pathological tumor regression grade, that is, good responders (TRG1-2) and poor responders (TRG3-5). Using binary logistic regression analysis with a cutoff value of P ≤ 0.2, promising predictive features for response were selected.; Results: Nineteen patients were included. Of these, 5 were good responders, and 14 were poor responders. Patient characteristics of these groups were similar at baseline. Fifty-seven features were extracted, of which 13 were found to be promising predictors of response. Baseline [T2: volume, diffusion-weighted imaging (DWI): apparent diffusion coefficient (ADC) mean, DWI: difference entropy], early response (T2: volume change, DWI: ADC mean change) and end-of-treatment presurgical evaluation MRI (T2: gray level nonuniformity, DWI: inverse difference normalized, DWI: gray level nonuniformity normalized), as well as baseline (metabolic tumor volume, total lesion glycolysis) and early response PET/CT (Δ maximum standardized uptake value, Δ peak standardized uptake value corrected for lean body mass), were promising features.; Conclusion: Both multiparametric MRI and [ 18 F]FDG PET/CT contain promising imaging features to predict response to neoadjuvant chemoradiotherapy in LARC patients. A future larger trial should investigate baseline, early response, and end-of-treatment presurgical evaluation MRI and baseline and early response PET/CT.; (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| References: | Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11:835–844.; Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol 2016; 23:1177–1186.; Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22:29–42.; Park JS, Baek JH, Lee WS, Yang JY, Lee WK, Kim KK, et al. Long-term oncologic outcomes in pathologic tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Korean J Clin Oncol 2018; 14:37–42.; Beets-Tan RGH, Lambregts DMJ, Maas M, Bipat S, Barbaro B, Curvo-Semedo L, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2018; 28:1465–1475.; Landelijke Werkgroep Gastro Intestinale Tumoren. Oncoline. https://www.oncoline.nl/colorectaalcarcinoom . [Accessed 6 November 2019].; van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet Lond Engl 2018; 391:2537–2545.; Hendren SK, O’Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005; 242:212–223.; Dutch Guideline Colorectal Cancer. Federation medical specialists. 2019. https://richtlijnendatabase.nl/richtlijn/colorectaal_carcinoom_crc . [Accessed 25 December 2021].; van Stiphout RGPM, Valentini V, Buijsen J, Lammering G, Meldolesi E, van Soest J, et al. Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: a multicentric prospective study with external validation. Radiother Oncol J Eur Soc Ther Radiol Oncol 2014; 113:215–222.; Janssen MHM, Öllers MC, van Stiphout RGPM, Riedl RG, van den Bogaard J, Buijsen J, et al. PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys 2012; 82:871–876.; Cliffe H, Patel C, Prestwich R, Scarsbrook A. Radiotherapy response evaluation using FDG PET-CT – established and emerging applications. Br J Radiol 2017; 90:20160764.; Joye I, Debucquoy A, Deroose CM, Vandecaveye V, Cutsem EV, Wolthuis A, et al. Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 2017; 124:104–109.; Mahadevan LS, Zhong J, Venkatesulu B, Kaur H, Bhide S, Minsky B, et al. Imaging predictors of treatment outcomes in rectal cancer: an overview. Crit Rev Oncol Hematol 2018; 129:153–162.; Meng X, Huang Z, Wang R, Yu J. Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Biosci Trends 2014; 8:11–23.; Giannini V, Mazzetti S, Bertotto I, Chiarenza C, Cauda S, Delmastro E, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features. Eur J Nucl Med Mol Imaging 2019; 46:878–888.; Joye I, Deroose CM, Vandecaveye V, Haustermans K. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol J Eur Soc Ther Radiol Oncol 2014; 113:158–165.; Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, et al. 18F-FDG PET/CT is an early predictor of pathologic tumor response and survival after preoperative radiochemotherapy with bevacizumab in high-risk locally advanced rectal cancer. J Nucl Med Off Publ Soc Nucl Med 2019; 60:1560–1568.; Schurink NW, Min LA, Berbee M, van Elmpt W, van Griethuysen JJM, Bakers FCH, et al. Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation. Eur Radiol 2020; 30:2945–2954.; Schurink NW, van Kranen SR, Berbee M, van Elmpt W, Bakers FCH, Roberti S, et al. Studying local tumour heterogeneity on MRI and FDG-PET/CT to predict response to neoadjuvant chemoradiotherapy in rectal cancer. Eur Radiol 2021; 31:7031–7038.; Maffione AM, Marzola MC, Capirci C, Colletti PM, Rubello D. Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am J Roentgenol 2015; 204:1261–1268.; Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al.; European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42:328–354.; Kikinis R, Pieper SD, Vosburgh KG. 3D slicer: a platform for subject-specific image analysis, visualization, and clinical support. In: Jolesz FA, editor. Intraoperative imaging and image-guided therapy. Springer; 2014. pp. 277–289. https://doi.org/10.1007/978-1-4614-7657-3_19 . [Accessed 16 December 2020].; van Griethuysen JJ, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res 2017; 77:e104–e107.; Delli Pizzi A, Chiarelli AM, Chiacchiaretta P, d’Annibale M, Croce P, Rosa C, et al. MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer. Sci Rep 2021; 11:5379.; van Timmeren JE, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B. Radiomics in medical imaging – ‘how-to’ guide and critical reflection. Insights Imaging 2020; 11:91.; O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 2016; 280:576–584.; Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73:2680–2686.; Peeters C, Übelhör C, Mes S, Martens R, Koopman T, Graaf P, et al. Stable prediction with radiomics data. 2019.; Gillies RJ, Kinahan PE, Hricak H. Radiomics:images are more than pictures, they are data. Radiology 2016; 278:563–577.; Uslu-Beşli L, Mermut O, Yardimci AH, Gündoğan C, Gürsu RU, Çermik TF. Comparison of 18F-FDG PET/CT and DW-MRI in assessment of neoadjuvant radiochemotherapy response in locally advanced rectal cancer patients. Rev Espanola Med Nucl E Imagen Mol 2021; 40:19–29.; Mes SW, van Velden FHP, Peltenburg B, Peeters CFW, Te Beest DE, van de Wiel MA, et al. Outcome prediction of head and neck squamous cell carcinoma by MRI radiomic signatures. Eur Radiol 2020; 30:6311–6321.; Schurink NW, van Kranen SR, Roberti S, van Griethuysen JJM, Bogveradze N, Castagnoli F, et al. Sources of variation in multicenter rectal MRI data and their effect on radiomics feature reproducibility. Eur Radiol 2022; 32:1506–1516. |
| Substance Nomenclature: | 0Z5B2CJX4D (Fluorodeoxyglucose F18); 0 (Radiopharmaceuticals) |
| Entry Date(s): | Date Created: 20230503 Date Completed: 20230609 Latest Revision: 20230917 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10246883 |
| DOI: | 10.1097/MNM.0000000000001703 |
| PMID: | 37132268 |
| Database: | MEDLINE |
Journal Article